SK4222002A3 - Vaccine - Google Patents

Vaccine Download PDF

Info

Publication number: SK4222002A3
Authority: SK; Slovakia
Prior art keywords: carrier; hpv; protein; human papillomavirus; antigens
Prior art date: 1999-09-30

Application number

SK422-2002A

Other languages

English (en)

Slovak (sk)

Inventor

Per Antonsson

Karin Kristensson

Marie Wallen-Ohman

Joakim Dillner

Peter Lando

Original Assignee

Active Biotech Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-30

Filing date

2000-09-19

Publication date

2002-10-08

2000-09-19 Application filed by Active Biotech Ab filed Critical Active Biotech Ab

2002-10-08 Publication of SK4222002A3 publication Critical patent/SK4222002A3/sk

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 15
241000701806 Human papillomavirus Species 0.000 claims abstract description 32
102000004169 proteins and genes Human genes 0.000 claims abstract description 26
108090000623 proteins and genes Proteins 0.000 claims abstract description 26
206010028980 Neoplasm Diseases 0.000 claims abstract description 21
108091033319 polynucleotide Proteins 0.000 claims abstract description 19
102000040430 polynucleotide Human genes 0.000 claims abstract description 19
239000002157 polynucleotide Substances 0.000 claims abstract description 19
108091034117 Oligonucleotide Proteins 0.000 claims abstract description 16
230000003472 neutralizing effect Effects 0.000 claims abstract description 13
238000000034 method Methods 0.000 claims abstract description 12
238000011161 development Methods 0.000 claims abstract description 10
238000002255 vaccination Methods 0.000 claims abstract description 10
239000000126 substance Substances 0.000 claims abstract description 4
108090000765 processed proteins & peptides Proteins 0.000 claims description 17
239000000427 antigen Substances 0.000 claims description 14
230000003612 virological effect Effects 0.000 claims description 14
102000036639 antigens Human genes 0.000 claims description 10
108091007433 antigens Proteins 0.000 claims description 10
230000001580 bacterial effect Effects 0.000 claims description 10
201000011510 cancer Diseases 0.000 claims description 10
210000004027 cell Anatomy 0.000 claims description 7
102000004196 processed proteins & peptides Human genes 0.000 claims description 7
208000009608 Papillomavirus Infections Diseases 0.000 claims description 6
230000003071 parasitic effect Effects 0.000 claims description 6
241000341655 Human papillomavirus type 16 Species 0.000 claims description 5
210000001744 T-lymphocyte Anatomy 0.000 claims description 5
208000021145 human papilloma virus infection Diseases 0.000 claims description 5
230000001681 protective effect Effects 0.000 claims description 5
230000004044 response Effects 0.000 claims description 5
208000035143 Bacterial infection Diseases 0.000 claims description 4
208000030852 Parasitic disease Diseases 0.000 claims description 4
208000036142 Viral infection Diseases 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 4
208000022362 bacterial infectious disease Diseases 0.000 claims description 4
101710125418 Major capsid protein Proteins 0.000 claims description 3
101800000874 Small capsid protein Proteins 0.000 claims description 3
150000001413 amino acids Chemical class 0.000 claims description 3
230000005875 antibody response Effects 0.000 claims description 3
230000004927 fusion Effects 0.000 claims description 3
230000003211 malignant effect Effects 0.000 claims description 3
210000003300 oropharynx Anatomy 0.000 claims description 3
210000003899 penis Anatomy 0.000 claims description 3
210000000664 rectum Anatomy 0.000 claims description 3
210000001215 vagina Anatomy 0.000 claims description 3
210000003905 vulva Anatomy 0.000 claims description 3
101710121996 Hexon protein p72 Proteins 0.000 claims description 2
230000003308 immunostimulating effect Effects 0.000 claims description 2
230000001939 inductive effect Effects 0.000 claims description 2
208000003154 papilloma Diseases 0.000 claims description 2
208000029211 papillomatosis Diseases 0.000 claims description 2
210000003800 pharynx Anatomy 0.000 claims description 2
230000005740 tumor formation Effects 0.000 claims 1
208000015181 infectious disease Diseases 0.000 abstract description 7
238000004519 manufacturing process Methods 0.000 abstract description 5
101710135729 Major capsid protein L1 Proteins 0.000 abstract 1
241001631646 Papillomaviridae Species 0.000 description 8
208000022361 Human papillomavirus infectious disease Diseases 0.000 description 6
206010008342 Cervix carcinoma Diseases 0.000 description 5
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
201000010881 cervical cancer Diseases 0.000 description 5
239000002245 particle Substances 0.000 description 5
108090000565 Capsid Proteins Proteins 0.000 description 4
102100023321 Ceruloplasmin Human genes 0.000 description 4
108020001507 fusion proteins Proteins 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
210000000234 capsid Anatomy 0.000 description 3
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 3
231100000590 oncogenic Toxicity 0.000 description 3
230000002246 oncogenic effect Effects 0.000 description 3
230000002265 prevention Effects 0.000 description 3
102000043129 MHC class I family Human genes 0.000 description 2
108091054437 MHC class I family Proteins 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
238000011282 treatment Methods 0.000 description 2
241000283690 Bos taurus Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
101710094648 Coat protein Proteins 0.000 description 1
102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
108700005307 Human papillomavirus HPV L1 Proteins 0.000 description 1
241000709701 Human poliovirus 1 Species 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
206010065764 Mucosal infection Diseases 0.000 description 1
101710141454 Nucleoprotein Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101710083689 Probable capsid protein Proteins 0.000 description 1
206010038707 Respiratory papilloma Diseases 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000005809 anti-tumor immunity Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
230000000521 hyperimmunizing effect Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000028802 immunoglobulin-mediated neutralization Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000012737 microarray-based gene expression Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
238000012243 multiplex automated genomic engineering Methods 0.000 description 1
102000027450 oncoproteins Human genes 0.000 description 1
108091008819 oncoproteins Proteins 0.000 description 1
229960002566 papillomavirus vaccine Drugs 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229940125575 vaccine candidate Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
Immunology (AREA)
Gynecology & Obstetrics (AREA)
Mycology (AREA)
Plant Pathology (AREA)
Otolaryngology (AREA)

SK422-2002A 1999-09-30 2000-09-19 Vaccine SK4222002A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9903534A SE514982C2 (sv)	1999-09-30	1999-09-30	Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
PCT/SE2000/001808 WO2001023422A1 (en)	1999-09-30	2000-09-19	Vaccine

Publications (1)

Publication Number	Publication Date
SK4222002A3 true SK4222002A3 (en)	2002-10-08

Family

ID=20417209

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK422-2002A SK4222002A3 (en)	1999-09-30	2000-09-19	Vaccine

Country Status (25)

Country	Link
EP (1)	EP1222200B1 (cs)
JP (1)	JP2003510064A (cs)
KR (1)	KR20020047195A (cs)
CN (1)	CN1373771A (cs)
AT (1)	ATE313559T1 (cs)
AU (1)	AU771481B2 (cs)
BR (1)	BR0014666A (cs)
CA (1)	CA2384723A1 (cs)
CZ (1)	CZ20021023A3 (cs)
DE (1)	DE60025016D1 (cs)
EE (1)	EE200200157A (cs)
HR (1)	HRP20020092A2 (cs)
HU (1)	HUP0202770A3 (cs)
IL (1)	IL148741A0 (cs)
MX (1)	MXPA02003328A (cs)
NO (1)	NO20020615L (cs)
NZ (1)	NZ516725A (cs)
PL (1)	PL355012A1 (cs)
RU (1)	RU2002111554A (cs)
SE (1)	SE514982C2 (cs)
SK (1)	SK4222002A3 (cs)
TR (1)	TR200200802T2 (cs)
WO (1)	WO2001023422A1 (cs)
YU (1)	YU22202A (cs)
ZA (1)	ZA200200886B (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY139500A (en) *	2003-11-12	2009-10-30	Merck Sharp & Dohme	Optimized expression of hpv 58 l1 in yeast
ATE466022T1 (de) *	2004-03-24	2010-05-15	Merck Sharp & Dohme	Optimierte expression von hpv-52-l1 in hefe
DE102004036913A1 (de) *	2004-07-16	2006-02-09	Responsif Gmbh	Verwendung von Pentameren zur Herstellung eines Medikaments
CN1796403B (zh) *	2004-12-22	2010-04-28	三峡大学	用于多型人乳头瘤病毒感染防治的多肽和疫苗
CN100392084C (zh) *	2006-03-13	2008-06-04	曾毅	含密码子优化型hpv16l1基因的重组腺病毒
CN101914139B (zh) *	2010-07-16	2012-11-21	四川大学	人类乳头瘤病毒(hpv)衣壳蛋白l1多肽及其制备与应用
CN110891602A (zh)	2017-06-23	2020-03-17	帕多瓦有限责任公司	嵌合病毒样颗粒以及其作为免疫反应的抗原特异性重定向剂的用途
JP7641005B2 (ja)	2018-12-27	2025-03-06	ヴェリミューンインコーポレイテッド	コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用
CN113454210A (zh) *	2019-02-08	2021-09-28	伦斯勒理工大学	基于精子相关蛋白catsper的避孕疫苗
MX2023004465A (es)	2020-10-19	2023-06-19	Verimmune Inc	Composiciones basadas en virus y métodos para redirigir respuestas inmunitarias preexistentes mediante su uso para el tratamiento del cáncer.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1728800A1 (de) *	1994-10-07	2006-12-06	Loyola University Of Chicago	Papillomavirusähnliche Partikel, Fusionsproteine sowie Verfahren zu deren Herstellung
FR2768749A1 (fr) *	1997-09-22	1999-03-26	Inst Nat Sante Rech Med	Virus artificiels derives de papillomavirus, et leurs utilisations, notamment en therapie genique
DE19812941A1 (de) *	1998-03-24	1999-10-07	Medigene Ag	Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor

1999
- 1999-09-30 SE SE9903534A patent/SE514982C2/sv not_active IP Right Cessation
2000
- 2000-09-19 DE DE60025016T patent/DE60025016D1/de not_active Expired - Lifetime
- 2000-09-19 KR KR1020027004124A patent/KR20020047195A/ko not_active Withdrawn
- 2000-09-19 PL PL00355012A patent/PL355012A1/xx not_active Application Discontinuation
- 2000-09-19 YU YU22202A patent/YU22202A/sh unknown
- 2000-09-19 RU RU2002111554/13A patent/RU2002111554A/ru unknown
- 2000-09-19 BR BR0014666-8A patent/BR0014666A/pt not_active IP Right Cessation
- 2000-09-19 SK SK422-2002A patent/SK4222002A3/sk unknown
- 2000-09-19 MX MXPA02003328A patent/MXPA02003328A/es unknown
- 2000-09-19 HU HU0202770A patent/HUP0202770A3/hu unknown
- 2000-09-19 EE EEP200200157A patent/EE200200157A/xx unknown
- 2000-09-19 IL IL14874100A patent/IL148741A0/xx unknown
- 2000-09-19 AU AU76951/00A patent/AU771481B2/en not_active Ceased
- 2000-09-19 JP JP2001526572A patent/JP2003510064A/ja active Pending
- 2000-09-19 TR TR2002/00802T patent/TR200200802T2/xx unknown
- 2000-09-19 CA CA002384723A patent/CA2384723A1/en not_active Abandoned
- 2000-09-19 CZ CZ20021023A patent/CZ20021023A3/cs unknown
- 2000-09-19 WO PCT/SE2000/001808 patent/WO2001023422A1/en not_active Ceased
- 2000-09-19 HR HR20020092A patent/HRP20020092A2/hr not_active Application Discontinuation
- 2000-09-19 AT AT00966633T patent/ATE313559T1/de not_active IP Right Cessation
- 2000-09-19 EP EP00966633A patent/EP1222200B1/en not_active Expired - Lifetime
- 2000-09-19 NZ NZ516725A patent/NZ516725A/xx unknown
- 2000-09-19 CN CN00812618A patent/CN1373771A/zh active Pending
2002
- 2002-01-31 ZA ZA200200886A patent/ZA200200886B/en unknown
- 2002-02-08 NO NO20020615A patent/NO20020615L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
HRP20020092A2 (en)	2003-06-30
YU22202A (sh)	2005-06-10
WO2001023422A1 (en)	2001-04-05
JP2003510064A (ja)	2003-03-18
ZA200200886B (en)	2003-03-26
EP1222200A1 (en)	2002-07-17
HUP0202770A2 (hu)	2002-12-28
AU771481B2 (en)	2004-03-25
DE60025016D1 (de)	2006-01-26
ATE313559T1 (de)	2006-01-15
BR0014666A (pt)	2002-06-18
TR200200802T2 (tr)	2002-09-23
NO20020615D0 (no)	2002-02-08
NZ516725A (en)	2003-03-28
IL148741A0 (en)	2002-09-12
CA2384723A1 (en)	2001-04-05
RU2002111554A (ru)	2004-03-27
SE514982C2 (sv)	2001-05-28
EE200200157A (et)	2003-04-15
NO20020615L (no)	2002-05-29
CZ20021023A3 (cs)	2002-07-17
HUP0202770A3 (en)	2004-07-28
AU7695100A (en)	2001-04-30
MXPA02003328A (es)	2004-09-10
SE9903534L (sv)	2001-03-31
PL355012A1 (en)	2004-03-22
EP1222200B1 (en)	2005-12-21
SE9903534D0 (sv)	1999-09-30
KR20020047195A (ko)	2002-06-21
CN1373771A (zh)	2002-10-09

Publication	Publication Date	Title
Jochmus et al.	1999	Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine
Karanam et al.	2009	Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection
Suzich et al.	1995	Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas.
EP1835029A1 (en)	2007-09-19	Papillomavirus vaccines
US5874089A (en)	1999-02-23	Protecting against canine oral papillomavirus (copy)
Fligge et al.	2001	Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33
Wu et al.	2015	Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach
Roden et al.	2003	Preventative and therapeutic vaccines for cervical cancer
Palmer et al.	2009	Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer
Ghim et al.	2004	Equine papillomavirus type 1: complete nucleotide sequence and characterization of recombinant virus-like particles composed of the EcPV-1 L1 major capsid protein
JP2002516291A (ja)	2002-06-04	パピローマウイルス・ウイルス様粒子による経口免疫感作
EP1222200B1 (en)	2005-12-21	Fusion protein between HPV-L1 and a peptide, capable of forming a VLP and that functions as a vehicle for introduction of a peptide in a cell and medical uses thereof
US7407807B2 (en)	2008-08-05	Chimaeric human papillomavirus 16 I1 virus like particles and a method for preparing the particles
US20040146531A1 (en)	2004-07-29	Virus-like particles devoid of HPV 16 type-specific antibody epitopes as carriers of peptides for introduction into cells
Ellis	1996	The new generation of recombinant viral subunit vaccines
Tindle	1997	Immunomanipulative strategies for the control of human papillomavirus associated cervical disease
Sapp et al.	1996	Synthesis, properties and applications of papillomavirus-like particles
WO1996033737A1 (en)	1996-10-31	Peptide-based vaccine against papillomavirus infection
Deng et al.	2011	The preparation of human papillomavirus type 58 vaccine and exploring its biological activity and immunogenicity in vitro
Kazaks et al.	2008	11 Papillomavirus-Derived Virus-Like Particles
Khan	1993	Cervical cancer, human papillomavirus and vaccines
JP2002509863A (ja)	2002-04-02	パピローマウイルス特異的腫瘍の回避用または治療用医薬
Wang et al.	2014	Virus-like particle vaccines for the prevention of human papillomavirus infection
Christensen	1999	Ricai Han, Nancy M. Cladel, Cynthia A. Reed, Xuwen Peng
Embers	2003	Immunogenicity and Cellular Protein Associations of the Papillomavirus Minor Capsid Protein